1. The effect of atrial natriuretic peptide on osmotically stimulated thirst appreciation and consequent fluid intake was investigated in healthy man. 2. Six seated male subjects were studied on two occasions: synthetic a-human atrial natriuretic peptide (99-126) (2 pmol min-' kg-') or placebo (saline, 150 mmol/l NaCI) was infused intravenously for 105 min; 30 min after the start of atrial natriuretic peptidelplacebo infusion, hypertonic saline (855 mmol/l NaCI) was infused (0.06 ml min-' kg-') for 60 min. Subjects were then allowed free access to water for the next 2 h; infusion of atrial natriuretic peptide/ placebo continued for the first 15min of the drinking period. 3. The plasma atrial natriuretic peptide concentration did not alter significantly during infusion of hypertonic saline and placebo; it rose to a steady state of 12.7+ 1.1 pmol/l mean+^^^) during the infusion of atrial natriuretic peptide and hypertonic saline, and remained at this level during the first 15min of the drinking period. During infusion of hypertonic saline and atrial natriuretic peptide or placebo, similar increases in plasma osmolality (P< 0.001) and plasma vasopressin concentration ( P < 0.005) occurred. During infusion of hypertonic saline and atrial natriuretic peptide or placebo, thirst increased significantly over the time course of both studies (P<O.Ol), but the effect of atrial natriuretic peptide infusion compared with placebo infusion was to significantly decrease thirst at 60 min. 4. Drinking rapidly abolished thirst and vasopressin secretion before changes in plasma osmolality occurred. Subjects drank significantly less water after atrial natriuretic peptide infusion compared with after placebo infusion (P< 0.01).
INTRODUCTION
Although the body has several intrinsic mechanisms to minimize water loss, thirst, the physiological drive to drink water, is essential to maintain fluid balance. Animal studies have demonstrated that the peripheral natriuretic and diuretic actions of atrial natriuretic peptide (ANP) [l] are matched by a central action to inhibit salt appetite [2] and water intake [3-91; it certainly makes teleological sense that a hormone which causes a diuresis should also inhibit fluid intake. To date, there have been few studies in man which have related thirst, drinking behaviour and circulating ANP concentration. Thirst is normally a continuous variable, rising when subjects are rendered increasingly hyperosmolar [lo] . However, we have previously shown that peripherally infused ANP blunts osmotically stimulated thirst appreciation in man [ll] . The aim of this study was to assess the effect of physiological increases in circulating ANP concentrations on actual fluid intake in hyperosmolar man. The results of this study have been published in abstract form [12] .
METHODS

Subjects
All subjects gave their informed consent to the studies, which had the approval of the local Ethical Committee. Six healthy male volunteers were studied on two occasions in random order separated by at least 1 month. They were aged 27f 1 years ( r n e a n f~~~) and were not taking any medication. Subjects abstained from alcohol and nicotine for 24h before the study; they fasted, but had free access to tap water from 24.00 hours on the evening before the study. seated position before the study began. Studies were performed seated, as in this position the release of ANP is not stimulated by hypertonic saline (HS) infusion [13] . Subjects were advised that they would receive an infusion of HS which might cause an increase in thirst [14] ; they were also told they would receive either ANP or a placebo infusion, although they would not know which until after both studies had been performed.
The visual analogue scale (VAS) for recording thirst comprised a lOcm uncalibrated line [lo] . The subjects were asked 'how thirsty do you feel? and told to mark the line at the point representative of their thirst between the extremes of very severe thirst at 10cm and no thirst at Ocm. At regular times during the study, this process was repeated on a separate line, but no reference was made to previous ratings. At each sampling time, the subjects were asked about possible symptoms of nausea and were also asked to report any other symptoms they might be experiencing, e.g. lethargy and drowsiness, in addition to their thirst appreciation. Two intravenous cannulae were inserted into the antecubital veins of one forearm, one for infusion of HS (855 mmol/l NaCl) and another for infusion of ANP/ placebo; a third cannula was inserted into the opposite forearm for blood sampling. Blood pressure and pulse were recorded at 15min intervals using an automatic sphygmomanometer (Accutorr, Cambridge, U.K.) attached over the brachial artery of the arm used for blood sampling. The amount of fluid consumed during the drinking period was assessed by using a measuring jug.
Sampling and analysis
A sample of blood was withdrawn at time -30min a n d . an infusion of synthetic a-human ANP (99-126) (Shire Pharmaceuticals, Andover, Hants, U.K.) in 60ml of vehicle (150mmol/lNaCl) (at 2pmol/min-' kg-') or placebo (saline, 150mmol/l) was started at a rate of 0.5ml/min and was continued for 105min.
At time zero (i.e. 30min after starting the ANP/ placebo infusion), an infusion of HS (855mmol/l NaCl) was begun at a rate of 0.06mlrnin-'kg-' and was continued for 1 h. Subjects were then allowed free access to tap water for the next 2h; infusion of ANP or placebo continued for the first 15 min of this 2 h period.
Blood was sampled at 15min intervals for the first 90min and at +5, +lo, +15, +30, +60 and + 120 min during the drinking period. Venous blood was withdrawn into cooled syringes and was transferred to chilled EDTA (potassium salt)/Trasylol (1000 kallikrein inhibitory units) tubes (4ml) and lithium heparin tubes (5 ml). Aliquots of blood were taken from the lithium heparin tubes into heparinized capillary tubes for duplicate measurement of packed cell volume (Hawkesley microhaematocrit centrifuge) and the remaining blood was centrifuged at 4°C for 20min (2000g). Within 5min of sampling, the plasma was separated and divided into aliquots for measurement of serum sodium concentration (ion-exchange electrode, Astra-8, Beckman), plasma osmolality (depression of freezing point method automatic micro-osmometer; Roebling) and plasma vasopressin concentration using a previously described r i a . (inter-and intraassay coefficients of variation 12.0% and 4.3% respectively; limit of detection 0.3 pmol of vasopressin/ litre of plasma) [l5] . Blood taken into EDTA (potassium salt)/Trasylol tubes was spun, separated and the plasma was stored at -80°C until measurement of plasma ANP concentration within 1 week by a sensitive and specific r i a . (inter-and intraassay coefficients of variation 13.1% and lO.l%, respectively; limit of detection 1.2 pmol of ANP/litre of plasma) [16] .
Statistics
Results are expressed as meansfSEM. For statistical purposes, the difference in thirst rating was calculated as the distance (in cm) of the subjects' mark from initial thirst at -30min [17] . Undetectable ANP concentrations were given a value of half the detection limit (i.e. 0.6pmol/l). Mean arterial blood pressure was calculated by adding one-third of the pulse pressure to the diastolic pressure. The change in blood volume was calculated using standard formulae [18] .
Two-way analysis of variance was performed on the data, and the significance of individual effects (i.e. time and treatment) was further analysed using Duncan's range test.
RESULTS
Both studies were well tolerated by all subjects and there were no side-effects associated with either study. Fig. 1 illustrates the changes in serum sodium concentration and plasma osmolality over the course of the studies. Serum sodium concentration rose from 139.7f0.2 to 145.0k0.9 mmol/l during infusion of placebo plus HS (P<O.OOl) and from 138.8k0.5 to 144.8k 1.2mmol/l during infusion of ANP plus HS (P<O.OOl); during the 2 h drinking period, serum sodium concentration fell to 141.5 k0.9 mmol/l during the placebo study ( P < 0.05) and to 140.5 f 0.3 mmol/l during the ANP study ( P < 0.05). Infusion of HS caused a progressive linear increase in plasma osmolality, from 286.5 f 0.8 to 295.5 f 1.2 mosmol/kg during placebo plus HS infusion ( P < 0.001) and from 285.6 f 1.4 to 295.8 k 1.2 mosmol/kg during ANP plus HS infusion placebo study ( P < 0.001) and to 289.3 k 1.8 mosmol/ kg during the ANP study (P<O.OOl). The plasma vasopressin concentration rose from 1.2 f 0.3 to 2.8 f0.8 pmol/l during placebo plus HS infusion ( P < 0.005) and from 0.9 L 0.2 to 2.6 k 0.9 pmol/l during ANP plus HS infusion (P<0.005). During the 2 h drinking period, plasma vasopressin concentrations fell to 0.6 f 0.3 mmol/l during the placebo study (P<O.OOl) and to 0.8 f0.5 mmol/l during the ANP study (P<O.OOl). There was no significant effect of ANP on plasma osmolality, serum sodium concentration or plasma vasopressin concentration compared with placebo. Fig. 2 illustrates the change in plasma ANP concentration, the change in the subjective rating of thirst over the course of the studies and the amount of fluid drunk during the drinking period. The plasma ANP concentration did not alter during the placebo plus HS study, but rose to a steady state of 12.7 f 1.1 pmol/l during the ANP plus HS study. Statistical significance: *P <0.05, **P <0.01 compared with placebo.
During the 2 h drinking period, the plasma ANP concentration did not change in the placebo study, but in the ANP study fell rapidly to basal levels once the ANP infusion was stopped. The plasma ANP concentration was significantly different from that in the control study at times -15, 0, 15, 30, 60, + 5 , +10 and +15min (P<0.05 or P<O.Ol: see Fig. 2 for individual values). The change in thirst was determined from the difference on the VAS from the value for each individual at initial thirst at -30 min. Thirst varied as an effect of both time and ANP/placebo infusion, and at 60 min ANP significantly depressed the thirst rating (placebo plus HS 4.3+0.9cm; ANP plus HS 1.8fl.lcm; P<0.05). There was a rapid fall in thirst appreciation during the drinking period in both studies (P<O.OOl). The higher plasma ANP concentrations during the first 15 min of drinking in the ANP study did not effect the fall in thirst appreciation, which varied only as a function of time.
The total amounts of water drunk at individual time points during the two studies are shown in Fig.  2 ; by 5min, subjects had drunk 41% (placebo study) and 33% (ANP study) of the total volume. At 15min, 60% of the total volume had been drunk in both studies. The amount of fluid drunk varied as an effect of both time and ANP/placebo infusion and at 30min subjects had drunk significantly more after the placebo infusion compared with after the ANP infusion (30min: placebo plus HS 928 f 102 ml; ANP plus HS 504f 145 ml, P <0.05); at 60min, the amounts drunk were 1095 f 134ml during placebo study and 595+119ml during the ANP study (P<O.Ol). By the end of the drinking period, subjects had drunk 1261+208ml in the placebo study, and 683fllOml in the ANP study Packed cell volume fell from 45.2f0.8% to 41.5f0.8% (P<0.05) during placebo plus HS infusion and from 45.2f 1.2 to 42.6f 1.1% during ANP plus HS infusion (not significant), which represent increases in blood volume of 7.9)2.5% and 5.7 + 1.6%, respectively. Packed cell volume varied as a result of time and not treatment in the placebo study. During the drinking period, packed cell volume rose to 43.5+0.8% in the placebo study (not significant) and to 43.0f 1.5% in the ANP study (not significant). Mean arterial blood pressure did not alter significantly over the time course of the two studies during either infusion of HS or the drinking period.
(P<O.Ol).
DISCUSSION
Human studies investigating the relationship between ANP, thirst and fluid intake are limited. We have previously used a VAS to provide a semiquantitative estimation of thirst, and demonstrated that ANP inhibits osmotically stimulated thirst in man [ll] . Owing to the study design, it was not possible to correlate the thirst estimate with fluid intake; in the present study, we have verified our estimates of thirst by assessing the amount of water drunk spontaneously after the hyperosmolar stimulus. The results show that a physiological increase in plasma ANP concentrations attenuates fluid intake in normal male subjects. We have also confirmed that peripherally infused ANP has no effect on osmotically stimulated vasopressin secretion [ 113, and that the release of ANP is not stimulated by drinking [19] .
Several aspects of the results merit further discussion. Despite a fall in plasma ANP concentrations and thirst ratings to basal values during the drinking period, the difference in fluid intake in ANP-infused, compared with placebo-infused, subjects persisted. It is known that the biological effects of ANP are prolonged compared with the plasma half-life, and one can speculate that ANP, remaining bound to its receptors after clearance from the plasma, continued to exert an inhibitory effect on fluid intake.
Similarly, despite a significantly lower cumulative fluid intake in ANP-infused subjects, there was no significant difference between the two studies in the final plasma osmolality or serum sodium concentration attained. This finding could be explained in terms of a persistent natriuretic action of ANP, by direct effects on glomerular filtration rate and segmental tubular transport [20] . This would lead to an enhanced natriuresis during the drinking period after the ANP infusion compared with the drinking period after the placebo infusion. Unfortunately, urinary sodium excretion was not measured during either study.
Blood volume increased during both studies, but this increase reached significance only during placebo plus HS infusion. The difference between the two studies is likely to be due to ANP-induced shifts in fluid from the intravascular compartment to the extravascular space possibly mediated by the action of ANP in increasing capillary permeability.
We have reported on the antidipsogenic effect of peripherally infused ANP on osmotically stimulated fluid intake in man, and similar results have been obtained after osmotic stimulation of thirst in the pig [9] . Studies in the rat, rabbit and pig have described the effect of peripherally or centrally infused ANP on extracellular thirst (haemorrhage, angiotensin 11, peritoneal dialysis); all studies showed inhibition of drinking [3, 4, 6, 8, 91 . Central and peripheral administration of ANP will also inhibit fluid intake in response to water deprivation (mixed cellular and extracellular stimulus) in the rat [3, 4, 51 and goat [7] , but not the rabbit [8] .
As both intravenous and central infusions of ANP inhibit drinking, the source and the site of action of endogenous atrial peptides involved in water intake are unclear. It was initially argued that any ANP detected in the central nervous system merely represented sequestration from plasma, but under normal circumstances ANP does not cross the blood-brain barrier [21] . A simple experiment using a r.i.a. indicated at least partial autonomy of brain ANP from that in the heart. After 3 days of water deprivation in the rat, there was a reduction in circulating ANP levels, an increase in atrial ANP content and a reduction in ANP-like immunoreactivity in areas both inside (suprachiasmatic nucleus, supraoptic nucleus) and outside (organum vasculosum of the lamina terminalis, neural lobe) the blood-brain barrier [22] .
Several groups [23-261 have reported ANPpositive neurons, fibres and binding sites in areas of the brain associated with the control of fluid and electrolyte balance, such as the hypothalamus and the circumventricular organs [27] . The presence of ANP mRNA within the brain indicates local synthe-sis [lo], and gives rise to the suggestion that brain ANP may exert a direct action on neural circuits involved in thirst and drinking behaviour. Further evidence in favour of a role for endogenous brain ANP in the maintenance of drinking is indicated by the observation that central administration of ANP antiserum potentiated water intake induced by water deprivation or angiotensin I1 [28]. It is now clear that, in addition to its role as a circulating hormone, ANP is a potential neurotransmitter.
However, as we and others have shown, peripheral infusions of ANP also inhibit fluid intake. It is possible that circulating ANP, of atrial origin, interacts with osmoreceptors on the circumventricular organs (subfornical organ and organum vasculosum of the lamina terminalis) where the blood-brain barrier is missing. As a result, information regarding the concentration of ANP in the circulation would be relayed to structures within the brain concerned with thirst and drinking be- 
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